India Biologics Safety Testing Market (2026-2031)
The India Biologics Safety Testing Market was valued at $118.5 Million in 2026 and projected to reach to $234.7 Million by 2031, representing a compound annual growth rate of 14.6%. India's biologics safety testing market is poised for significant growth as the country solidifies its position as a global biopharmaceutical manufacturing hub.
India Biologics Safety Testing Market Trends and Insights
- This growth trajectory reflects India's strengthening position as a global biopharmaceutical hub and increasing regulatory scrutiny around biologics manufacturing.
- India's market expansion is driven by rising investments in biosimilar development, enhanced quality control standards, and growing demand for contract research and manufacturing services across the country. The biologics safety testing sector in India is benefiting from the nation's cost-competitive advantage and skilled workforce in pharmaceutical research.
- India's regulatory framework has become increasingly stringent, necessitating comprehensive safety testing protocols for biologics manufacturers.
- Between 2026 and 2031, India is expected to witness accelerated adoption of advanced testing technologies and methodologies, positioning the country as a critical player in the Asia Pacific biologics safety testing landscape..
Key Market Statistics
- CAGR (2026-2031) 14.6% CAGR
- Market Size, 2026 ~USD 118.5 Million
- Forecast, 2031 ~USD 234.7 Million
- Country India
India Biologics Safety Testing Market Overview
Rapid Market Expansion :
India's biologics safety testing market is projected to grow from USD 118.5 million in 2026 to USD 234.7 million by 2031, representing a robust 14.6% CAGR, outpacing the global growth rate of 11.6%.
Biosimilar Development Hub :
India's emergence as a global biopharmaceutical manufacturing center is driving demand for comprehensive safety testing services, with increasing investments in biosimilar development and manufacturing capabilities.
Regulatory Compliance Pressure :
Stringent regulatory requirements from Indian authorities and international bodies are compelling biologics manufacturers to invest heavily in safety testing infrastructure and quality assurance protocols.
Cost-Competitive Advantage :
India's lower operational costs combined with skilled scientific workforce make it an attractive destination for biologics safety testing, attracting both domestic and international pharmaceutical companies.
India Biologics Safety Testing Market Dynamics
- The market expansion is fueled by increasing investments in biosimilar development, rising regulatory scrutiny, and the need for comprehensive safety testing protocols.
- Domestic pharmaceutical companies are scaling up their R&D capabilities while international players are establishing testing facilities in India to leverage cost advantages and skilled talent. The forecast period through 2031 will witness accelerated adoption of advanced safety testing technologies, including in vitro and in vivo testing methodologies.
- Government initiatives supporting pharmaceutical innovation, coupled with growing demand for biologics in treating chronic diseases, will further propel market growth.
- India's competitive pricing and regulatory expertise position it as a preferred destination for global biologics safety testing outsourcing..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- India's biologics safety testing market will nearly double from USD 118.5M (2026) to USD 234.7M (2031), representing a 14.6% CAGR.
- India's biosimilar manufacturing boom is driving demand for comprehensive safety testing and regulatory compliance services.
- India's cost advantage and regulatory improvements position the country as a preferred destination for global biologics testing outsourcing.
- India's market growth outpaces the global average (14.6% vs. 11.6%), reflecting accelerated biopharmaceutical sector development.
Biologics Safety Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | STERILITY TESTING SERVICES (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 11.6% from 2026 to 2031 |
| Largest Segment | SERVICES (Offering) |
| Market Size Base Year (Billions) | ~USD 5.58 (2026) |
| Revenue Forecast (Billions) | ~USD 9.66 (2031) |
| Segments Covered | Offering, Type, Product & Service, Test Type, Application, End User |
India Biologics Safety Testing Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Bioburden Testing Services
- Endotoxin Testing Services
- Mycoplasma Testing Services
- Other Biologics Safety Testing Services
- Other Bst Services
- Sterility Testing Services
- Virus Safety Testing Services
By Product & Service
- Consumables
- Instruments
- Services
By Test Type
- Bioburden Tests
- Endotoxin Tests
- Mycoplasma Tests
- Other Biologics Safety Tests
- Residual Host Cell Proteins & Dna Detection Tests
- Sterility Tests
- Virus Safety Tests
By Application
- Blood & Blood Products Development And Manufacturing
- Cellular & Gene Therapy Products Development And Manufacturing
- Monoclonal Antibodies Development And Manufacturing
- Other Applications
- Vaccines Development And Manufacturing
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Pharmaceutical & Biotechnology Companies
Target Audience
- Biopharmaceutical Manufacturers : Indian and multinational biologics manufacturers need market insights to plan safety testing investments, optimize R&D budgets, and identify outsourcing opportunities aligned with India's growing testing infrastructure.
- Contract Research Organizations (CROs) : CROs operating in India require detailed market data to assess demand for safety testing services, benchmark pricing strategies, and identify expansion opportunities in the rapidly growing biosimilar testing segment.
- Private Equity & Investors : Investment firms evaluating opportunities in India's biopharmaceutical sector need validated market projections and growth drivers to assess portfolio companies, fund allocation, and acquisition targets in safety testing.
- Regulatory & Quality Assurance Teams : Compliance professionals and quality heads require India-specific regulatory landscape analysis to understand evolving safety testing requirements, benchmark standards, and ensure adherence to local and international guidelines.
- Government & Policy Bodies : Indian pharmaceutical regulatory authorities and policy makers need market intelligence to inform industry support initiatives, infrastructure development, and policies promoting India's biologics safety testing capabilities.
Key Companies in the India Biologics Safety Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Drug Product Services (finished dosage manufacturing, packaging, lifecycle management),Pharmaceutical Development Services (formulation, clinical trial supply),Drug Substance Services (API and biologics substance), |
| SIGMA-ALDRICH CORPORATION | United States | Private Company | Chemicals and Biochemicals Catalog,Cell Culture, Media, and Critical Raw Materials,Filtration, Labware, and Water Purification, |
| WUXI PHARMATECH (CAYMAN) INC | China | Private Company | Chemistry drug CRDMO services,Biology discovery and preclinical testing,Clinical research services, |
| FLUOR CORPORATION | United States | Public Company | Energy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining, infrastructure, staffing, maintenance),Mission Solutions (government, nuclear remediation, security, logistics, O&M), |
| AZELIS HOLDINGS SA | Belgium | Private Company | Coatings, Plastics & Advanced Materials Specialties,Food & Nutrition Ingredients,Personal Care & Home Care Ingredients, |
| CATALENT, INC. | United States | Private Company | Biologics (proteins, cell and gene, parenteral, large-molecule analytics),Pharma and Consumer Health – softgels and advanced oral dose (incl. Zydis),Pharma and Consumer Health – other oral, nasal, inhaled, topical, |
PATHEON INC
Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and biotechnology services sector.
SIGMA-ALDRICH CORPORATION
Sigma-Aldrich Corporation is a United States-based private company founded in 1951 with 9,800 employees specializing in life science and chemical products.
WUXI PHARMATECH (CAYMAN) INC
Wuxi Pharmatech (Cayman) Inc. is a China-based private company founded in 2000 with 8,837 employees providing pharmaceutical research and development services.
FLUOR CORPORATION
Fluor Corporation is a United States-based public company founded in 1912 with 22,995 employees operating in engineering, procurement, and construction services.
AZELIS HOLDINGS SA
Azelis Holdings SA is a Belgium-based private company founded in 2001 with 1,325 employees specializing in specialty chemicals and ingredients.
CATALENT, INC.
Catalent, Inc. is a United States-based private company founded in 1933 with 16,900 employees offering pharmaceutical development and manufacturing services.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation for India (USD 118.5M in 2026) with verified 14.6% CAGR projections through 2031, enabling accurate financial forecasting and investment planning specific to the Indian market.
- Competitive Positioning Intelligence : Understand India's market dynamics relative to global trends (11.6% CAGR), identifying competitive advantages and market gaps to inform strategic expansion and partnership decisions in the region.
- Regulatory & Compliance Insights : Access detailed analysis of India-specific regulatory requirements driving safety testing demand, helping manufacturers align operations with local compliance standards and international expectations.
- Investment & Expansion Strategy : Leverage India-focused market data to evaluate facility establishment, outsourcing partnerships, and resource allocation decisions in one of the fastest-growing biologics testing markets globally.
- Stakeholder Decision Support : Provide board-level executives, investors, and operational teams with credible India market intelligence to support M&A decisions, capacity planning, and go-to-market strategies in the biopharmaceutical sector.
Frequently asked questions
What is the current size of India's biologics safety testing market?
India's biologics safety testing market is valued at USD 118.5 million in 2026 and is projected to grow to USD 234.7 million by 2031.
What is the growth rate of India's biologics safety testing market?
India's biologics safety testing market is growing at a compound annual growth rate (CAGR) of 14.6% from 2026 to 2031.
Why is India's biologics safety testing market growing faster than the global average?
India's market growth (14.6% CAGR) exceeds the global rate (11.6%) due to increased biosimilar manufacturing, regulatory enhancements, and India's position as a cost-competitive biopharmaceutical hub.
What factors are driving demand for biologics safety testing in India?
Key drivers include rising biosimilar development investments, stringent regulatory requirements, growing contract research and manufacturing services, and India's skilled pharmaceutical workforce.
How will India's biologics safety testing market evolve by 2031?
By 2031, India's market is expected to reach USD 234.7 million with accelerated adoption of advanced testing technologies, positioning India as a critical Asia Pacific player in biologics safety testing.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the biologics safety testing market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the US Food and Drug Administration (FDA), World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), News Articles, Press Releases. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global biologics safety testing market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the biologics safety testing market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The biological safety testing market comprises the products and services used to assess the safety, purity, potency, and quality of biologically derived products across their development, manufacturing, and release stages.
Key Stakeholders
- Biologics safety testing products and services companies
- National and regional research boards and organizations
- Research & development companies
- Clinical research organizations (CROs)
- Biotechnology companies
- Research laboratories & academic institutes
- Market research & consulting firms
- Regulatory bodies
Report Objectives
- To define, describe, and forecast the biologics safety testing market by offering, test type, product application, service application, product end user, service end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biologics safety testing market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe biologics safety testing market, by country
- Further breakdown of the Rest of Asia Pacific biologics safety testing market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Get the Full Biologics Safety Testing Market Report
Full forecast, segment splits, and company analysis for all Biologics Safety Testing Market.
- US Biologics Safety Testing Market
- Canada Biologics Safety Testing Market
- UK Biologics Safety Testing Market
- Germany Biologics Safety Testing Market
- France Biologics Safety Testing Market
- Italy Biologics Safety Testing Market
- Spain Biologics Safety Testing Market
- China Biologics Safety Testing Market
- Japan Biologics Safety Testing Market
- South Korea Biologics Safety Testing Market
- Australia Biologics Safety Testing Market
- Brazil Biologics Safety Testing Market
- Mexico Biologics Safety Testing Market
- Saudi Arabia Biologics Safety Testing Market
- UAE Biologics Safety Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report